Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS)

Br J Haematol. 2019 Feb;184(3):472-475. doi: 10.1111/bjh.15120. Epub 2018 Feb 9.

Authors

Lucie Demaria¹, Julien Henry¹, Raphaele Seror^{1

2}, Laurent Frenzel^{3

4}, Olivier Hermine^{3

4}, Xavier Mariette^{1

2}, Gaetane Nocturne^{1

2}

Affiliations

¹ Department of Rheumatology, AP-HP, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.
² INSERM U1184, Center for immunology of viral infections and autoimmune diseases, Université Paris-Sud, Le Kremlin-Bicêtre, France.
³ Department of Clinical Haematology, AP-HP, Necker Hospital, Paris, France.
⁴ Institut Imagine, NSERM U 1163/CNRS ERL 8254, Paris, France.

PMID: 29424433
DOI: 10.1111/bjh.15120

No abstract available

Keywords: Sjögren syndrome; bendamustine; mucosa associated lymphoid tissue lymphoma.

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Bendamustine Hydrochloride / administration & dosage
Female
Humans
Lymphoma, B-Cell, Marginal Zone / drug therapy*
Male
Middle Aged
Retrospective Studies
Rituximab / administration & dosage
Sjogren's Syndrome / drug therapy*

Substances

Rituximab
Bendamustine Hydrochloride